Takeda Announces Divestment of Multilab to Novamed

April 5, 2018

Osaka, Japan, April 5, 2018 Takeda Pharmaceutical Company Limited (TSE: 4502) today announced it has signed an agreement with Novamed Fabricação de Produtos Farmacêuticos Ltda., (Novamed), to sell/divest all shares, and all its assets in, Multilab Indústria e Comércio de Produtos Farmacêuticos Ltda. to Novamed.

Takeda is committed to continuing to help meet the unmet needs of patients in Brazil and to maintaining its ‘best-in-class’ position in its core therapeutic areas, including Gastroenterology and Oncology. Taking into careful consideration the future development of Multilab's business, Takeda is confident that Novamed, part of the NC Group which owns some of the largest pharmaceutical companies in Brazil, will develop the future business of Multilab by leveraging the synergies of both companies.

1. Overview of Multilab

(1)

Company name

Multilab Indústria e Comércio de Produtos Farmacêuticos Ltda.

(2)

Headquarters

São Jerônimo, Rio Grande do Sul, Brazil

(3)

Name of representative

Renata Rodrigues Campos

(4)

Business description

Research, development, manufacturing and sales of pharmaceutical products

(5)

Capital

BRL 688 million

(6)

Date of establishment

1988

(7)

Major shareholders and percentage of shares held

Takeda Pharma A/S

100%

(8)

Relationships between Takeda and Multilab

Capital relationship

Takeda Pharmaceutical Company Limited holds all the outstanding shares of Takeda Pharma A/S, which holds all of the outstanding shares of Multilab.

Personnel relationship

Not Applicable

Transactional relationship

Not Applicable

(9)

Operating result and financial conditions for the last three years

Accounting period

Fiscal year ended March 2015

Fiscal year ended March 2016

Fiscal year ended March 2017

 Net assets (million yen)

16,800

10,612

10,276

 Total assets (million yen)

21,197

19,175

20,916

 Net assets per share (yen)

31.99

20.21

17.58

 Sales (million yen)

7,473

5,701

5,390

 Operating income
(million yen)

-1,831

-2,057

-2,292

Net income (million yen)

-1,917

-3,499

-3,664

 Earnings per share (yen)

-3.65

-6.66

-6.42


2.  Overview of Novamed
Company name                     : Novamed Fabricação de Produtos Farmacêuticos Ltda.
Location                                : Brazil


Relationships between Takeda:

Capital relationship

Not Applicable

Personnel relationship

Not Applicable

Transactional relationship

Not Applicable

Whether Novamed constitutes a related party

Not Applicable



3.
 Change in Ownership Ratio of Shares through the Divestment

(1)

Number of shares held prior to the divestment

688,217,037 shares

(Takeda Pharma A/S: 688,217,037 shares)

(Number of votes:688,217,037)

(% of total votes:100%)


(2)

Number of shares to be divested

688,217,037 shares

(Takeda Pharma A/S: 688,217,037 shares)

(Number of votes:688,217,037)

(3)

Number of shares held after the divestment

0 shares

(Number of votes:0)

(% of total votes:0.00%)

The divestment price is undisclosed in accordance with an agreement with Novamed, and was assessed rationally based on discussions between Takeda and Novamed.


4. Schedule of the Divestment

(1)

Date of governance meeting resolution

March 20, 2018

(2)

Date of conclusion of the agreement

March 22, 2018

(3)

Date of transfer of shares

June, 2018 (TBC)



5. Outlook
The impact of the divestment on Takeda's consolidated results for FY2017 is minimal. Takeda’s financial forecast for FY2018, including the impact of this divestment, will be announced in May 2018.
 


Media Contacts:

Media outside Japan
Vince Docherty
vince.docherty@takeda.com
+65 8332 4233

Japanese Media
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095